- Halozyme has settled into its role as a royalty cash machine after transitioning away from a drug discovery company, and the immediate future looks very bright.
- With 5 products currently on the market and 11 trials ongoing using its technology, growing its royalty revenue and profits looks certain.
- Patent cliffs provide a relatively concrete end date to the growth story and the company has indicated its intention to pursue M&A to continue growth after 2027.
For further details see:
Halozyme: 7 Years Of Royalty Bliss Coming; Afterwards, Questions To Answer